This international prognostic index (IPI) score calculator for lymphoma prognosis stratifies survival rates based on risk factors in the original and revised IPI scores. There is in depth information about the two versions of this lymphoma prognostic index and also about an age adjusted short model, in the text below the form.
How does the international prognostic index (IPI) score calculator for lymphoma prognosis work?
This health tool presents the IPI and revised IPI scores in order to help the outcome prognosis of patients with aggressive non-Hodgkin’s lymphoma.
Developed in 1993 to accurately predict survival outcomes, the 2031 patient clinical trial involved a sample of patients of different ages, diagnosed with aggressive NHL and who were treated with a doxorubicin-based chemotherapy regimen such as CHOP 10 to 6 years before the study.
The five risk factors taken into account in the IPI score calculator for lymphoma prognosis are:
■ Age greater than 60 years;
■ Stage III or IV disease (according to the Ann Arbor staging system);
■ Elevated serum lactate dehidrogenase;
■ ECOG performance status of 2 – 4;
■ Two or more extranodal sites of disease.
Each present risk factors adds one point to the overall score. All possible results and their survival rates can be found in the table below.
|IPI score||Risk group||5-year survival||5-year survival according to PTCL*||3-year survival according to CDBCL*|
|0 - 1||Low||73%||91%||50%|
|2||Low - intermediate||51%||81%||33%|
|3||High - intermediate||43%||65%||16%|
|4 - 5||High||26%||59%||11%|
*Where PTCL refers to the International Peripheral T-cell Lymphoma Project and CDBCL refers to the CD20+ B-cell lymphoma study in reference no. 3.
One of the criticisms received by the model concerns the fact that its was developed before the introduction of rituximab therapy which is now included in the standard therapeutic management of B-cell lymphomas.
The new therapy has significantly improved outcomes of lymphoma patients but its effect on IPI has not been evaluated entirely.
There is also an age-adjusted IPI for use in clinical trials. This derived method takes out the age and extranodal site factors from the original IPI under the assumption that the patients compared are within the same age group, either below or over 60.
The three factors which remain in the age-adjusted version are the malignancy stage, LDH and performance status.
The table below introduces the correlation between the adjusted scores and predicted survival:
|IPI score||Risk group||5-year survival|
|1||Low - intermediate||69%|
|2||High - intermediate||46%|
Revised international prognostic index (rIPI)
The study cited in reference no. 3 suggests that the IPI remains a valid predictor outcome in patients with aggressive B-cell lymphoma under therapy with a combination of rituximab and CHOP.
However, a new revised version of IPI has been build and consists of the following changes:
■ One change of risk factor – ECOG performance scale 3 or greater (the original IPI factor was ECOG 2 or greater).
■ Change of risk classification scale – The new scale has the following groups: good, intermediate and poor while the original study was low, low – intermediate, high – intermediate and high.
■ Change in survival rates – the Revised version accounts for the 4-year progression free survival, compared to the 5-year median survival in the IPI.
|Revised IPI score||Risk group||4-year progression free survival|
|1 - 2||Intermediate||80%|
|3 - 5||Poor||53%|
Along the internal prognostic index, there are other survival stratificiation tools addressed to lymphoma conditions such as the FLIPI score for follicular lymphoma or the MIPI score for mantle cell lymphoma.
1) (1993) . N Engl J Med; 329(14):987-94.
2) Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, Rüdiger T, Pileri S, Nakamura S, Nathwani B, Campo E, Berger F, Coiffier B, Kim WS, Holte H, Federico M, Au WY, Tobinai K, Armitage JO, Vose JM; International Peripheral T-cell Lymphoma Project. (2011) . Blood; 117(12):3402-8.
3) Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, Loeffler M. (2010) . J Clin Oncol; 28(14):2373-80.
4) Geisler CH, et al. (2010) . Blood; 115:1530–3.
5) Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM. (2007) . Blood; 109(5):1857-61.
6) Todorovic M, Balint B, Andjelic B, Stanisavljevic D, Kurtovic NK, Radisavljevic Z, Mihaljevic B. (2012) . Medical Oncology; (29)3, pp 2212–2219.01 Sep, 2016 | 0 comments